Learn About Plasmacytoma

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Plasmacytoma Local Doctors?
PM
Philippe R. Moreau
Philippe R. Moreau
Elite
Highly rated in
19
conditions

Université De Nantes

Nantes, FR 

Philippe Moreau is in Nantes, France. Moreau is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Leukemia.

View Profile
RH
Roman Hajek
Elite
Highly rated in
25
conditions

University Of Ostrava

Faculty Of Medicine 
Ostrava, MO, CZ 

Roman Hajek is in Ostrava, Czech Republic. Hajek is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Monoclonal Gammopathy of Undetermined Significance, and Bone Marrow Transplant.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
MC
Michele Cavo
Elite
Highly rated in
26
conditions

University Of Bologna

Diagnostic And Specialty Medicine 
Bologna, IT 

Michele Cavo is in Bologna, Italy. Cavo is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. They are also highly rated in 26 other conditions, according to our data. Their top areas of expertise are Multiple Myeloma, Myelofibrosis, Bone Marrow Transplant, and Leukemia.

View Profile
View All Doctors
What are the Latest Advances for Plasmacytoma?
Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Condition: Plasmacytoma
Journal: Annals of hematology
Treatment Used: Autologous Stem Cell Transplantation (ASCT)
Number of Patients: 303
Published: April 21, 2022
View publication
Summary: Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.
Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Condition: Multiple Myeloma (MM)
Journal: Annals of agricultural and environmental medicine : AAEM
Treatment Used: Ixazomib-Lenalidomid-Dexamethasone
Number of Patients: 9
Published: March 30, 2022
View publication
Summary: Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Tired of the same old research?
Check Latest Advances
Clinical analysis of 10 cases with extramedullary plasmacytoma of the head and neck.
Condition: Extramedullary Plasmacytoma of Head and Neck
Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Treatment Used: Surgery, Adjuvant Radiotherapy, or Radiotherapy Alone
Number of Patients: 10
Published: February 23, 2022
View publication
Summary: Clinical analysis of 10 cases with extramedullary plasmacytoma of the head and neck.
View All Latest Advances
What are the latest Plasmacytoma Clinical Trials?
Dysregulation of Hematopoiesis in Fanconi Anemia
Status: Active, not recruiting
Start Date: June 1975
Intervention Type: Genetic, Other
View Trial
Summary: RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers.~PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myelopr...
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.
Who is this study for: Patients with Multiple Myeloma
Status: Active, not recruiting
Start Date: May 29, 2014
Intervention Type: Drug
Study Drugs: Lenalidomide, Pomalidomide, Intensol, Daratumumab
Phase: Phase 2
View Trial
Summary: This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of lenalidomide-based therapy.~This trial will tes...
View All Clinical Trials